Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / chronic weight management | Varies by plan |
| Moderate-to-severe obstructive sleep apnea in adults with obesity | Covered with prior authorization |
Plan type: Commercial non-Medicare. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
This varies by plan. BCBSIL's pharmacy benefit runs through Prime Therapeutics. Coverage of GLP-1 and anti-obesity drugs, including Zepbound, is an optional benefit that varies by employer group. BCBSIL states the categories and medications included may vary according to employer group selections, and that benefits are subject to the member's certificate of coverage (bcbsil.com/provider/education/education-reference/news/2024/08-12-2024-30-day-supply-limit). Prime's weight-management criteria approve the obesity indication only when obesity is not restricted from coverage under the patient's benefit. The obstructive sleep apnea indication is reviewed as a separate medical indication and does not carry that benefit-exclusion gate. Members should confirm their own certificate of coverage before assuming coverage.
Coverage by indication
| BMI threshold | 30 or higher, or 27 or higher with at least one weight-related comorbidity; 25 or higher for adults of South Asian, Southeast Asian, or East Asian descent |
What the prior authorization needs:
- Obesity is not restricted from coverage under the patient's benefit (employer-elected; many groups exclude anti-obesity drugs)
- Adult (18 or older) with BMI 30 or higher, or 27 or higher with a weight-related comorbidity such as hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, or dyslipidemia (25 or higher for South, Southeast, or East Asian descent)
- At least 6 months on a reduced-calorie diet, increased physical activity, and behavioral modification, continued alongside the drug
- No formal step through Wegovy. Criteria require that no targeted weight-loss agent (Saxenda, Wegovy, Zepbound) was tried in the past 12 months, or that the prescriber anticipates success with a repeat course
- Not used in combination with another GLP-1 receptor agonist or other weight-loss drug
- No FDA-labeled contraindication (for example personal or family history of medullary thyroid carcinoma or MEN 2)
- Quantity limit applies (for example 4 pens or 4 vials per 28 days; 2.5 mg starter 4 per 180 days). Initial approval 12 months; renewal needs 5% or more weight loss or under 52 weeks on the maximum-tolerated dose
Policy Choice_Commercial_PS_Weight_Management_PAQL_ProgSum_07-01-2026_v4. Source: Weight Management Prior Authorization with Quantity Limit Program Summary (Prime Therapeutics, effective 07-01-2026). pbm-policy. Verified August 28, 2026.
| BMI threshold | 30 or higher |
What the prior authorization needs:
- Diagnosis of obstructive sleep apnea confirmed by polysomnography or a home sleep apnea test
- Apnea-hypopnea index (AHI) of 15 or higher events per hour at baseline, before starting drug therapy
- BMI 30 or higher
- On a reduced-calorie diet, increased physical activity, and behavioral modification, continued alongside the drug
- Not used in combination with another GLP-1 receptor agonist; no FDA-labeled contraindication
- Reviewed as a separate FDA-approved medical indication, not gated on the obesity benefit exclusion. Initial approval 12 months; renewal needs documented clinical benefit such as a reduced AHI
Policy Choice_Commercial_PS_Weight_Management_PAQL_ProgSum_07-01-2026_v4. Source: Weight Management Prior Authorization with Quantity Limit Program Summary (Prime Therapeutics, effective 07-01-2026). pbm-policy. Verified August 28, 2026.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time. Some participants get a placebo, decided at random.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does BCBS Illinois cover Zepbound?
Whether Blue Cross and Blue Shield of Illinois covers Zepbound for weight loss depends on the employer group. BCBSIL runs its drug benefit through Prime Therapeutics, and weight-management drug coverage varies by the group's benefit selection, with many groups excluding anti-obesity drugs. Where the benefit is included, Zepbound needs prior authorization at a BMI of 30 or higher (or 27 or higher with a weight-related condition) plus at least 6 months of a reduced-calorie diet, physical activity, and behavioral changes. Zepbound is also covered for moderate-to-severe obstructive sleep apnea in adults with obesity, which is reviewed as a separate medical indication. This reflects the published policy verified August 2026.
What does BCBS Illinois require to approve Zepbound?
For moderate-to-severe obstructive sleep apnea in adults with obesity: The BMI requirement is 30 or higher.
Why might BCBS Illinois deny Zepbound even if I meet the criteria?
BCBSIL's pharmacy benefit runs through Prime Therapeutics. Coverage of GLP-1 and anti-obesity drugs, including Zepbound, is an optional benefit that varies by employer group. BCBSIL states the categories and medications included may vary according to employer group selections, and that benefits are subject to the member's certificate of coverage (bcbsil.com/provider/education/education-reference/news/2024/08-12-2024-30-day-supply-limit). Prime's weight-management criteria approve the obesity indication only when obesity is not restricted from coverage under the patient's benefit. The obstructive sleep apnea indication is reviewed as a separate medical indication and does not carry that benefit-exclusion gate. Members should confirm their own certificate of coverage before assuming coverage.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
